Payment overview · 2025
General Payments
$851.58
26 reported records · 13 companies
Healthcare provider profile · identity verified
Jonathan Swetech, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLINTON TOWNSHIP, MI · NPI 1871909598
Verified facts
What the public records show
CMS Open Payments records show Jonathan Swetech, D.O. received $851.58 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $379.93 | 44.6% | 9 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $105.67 | 12.4% | 2 | 2025 |
| BSN Medical Inc | Unresolved — no canonical attribution shown | $72.38 | 8.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.95 | 7.4% | 3 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $38.32 | 4.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $37.04 | 4.3% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $32.56 | 3.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.39 | 3.7% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $20.58 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.49 | 2.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.11 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.79 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.37 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $851.58 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $379.93 | 9 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $105.67 | 2 | 2025 |
Source payment records
|
|||||
| JOBST SPORT Normalized: jobst sport |
Device | BSN Medical Inc | $72.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $38.32 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $37.04 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $32.56 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $32.56 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.39 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 97 |
| Metformin Hcl | Metformin Hcl | 239 | 79 |
| Lisinopril | Lisinopril | 233 | 71 |
| Omeprazole | Omeprazole | 158 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 123 | 42 |
| Prednisone | Prednisone | 122 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 42 |
| Montelukast Sodium | Montelukast Sodium | 109 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 39 |
| Losartan Potassium | Losartan Potassium | 90 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 44 |
| Baclofen | Baclofen | 71 | 35 |
| Carvedilol | Carvedilol | 66 | 17 |
| Simvastatin | Simvastatin | 66 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 20 |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 56 | 43 |
| Alendronate Sodium | Alendronate Sodium | 49 | 18 |
| Azithromycin | Azithromycin | 46 | 34 |
| Ketoconazole | Ketoconazole | 46 | 24 |
| Furosemide | Furosemide | 45 | 20 |
| Buspirone Hcl | Buspirone Hcl | 44 | 21 |
| Anastrozole | Anastrozole | 43 | 18 |
| Ibuprofen | Ibuprofen | 43 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Allopurinol | Allopurinol | 40 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 17 |
| Topiramate | Topiramate | 39 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | 23 |
| Eliquis | Apixaban | 37 | 13 |
| Glimepiride | Glimepiride | 36 | 11 |
| Sucralfate | Sucralfate | 35 | 23 |
| Acarbose | Acarbose | 34 | 15 |
| Potassium Chloride | Potassium Chloride | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 17 |
| Gabapentin | Gabapentin | 32 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 13 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 12 |
| Donepezil Hcl | Donepezil Hcl | 29 | 11 |
| Trazodone Hcl | Trazodone Hcl | 29 | 12 |
| Famotidine | Famotidine | 28 | 17 |
| Meloxicam | Meloxicam | 28 | 13 |
| Ozempic | Semaglutide | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | 12 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Indomethacin | Indomethacin | 27 | 15 |
| Mupirocin | Mupirocin | 27 | 21 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 20 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 17 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Lactulose | Lactulose | 25 | 20 |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 12 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | 11 |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | 11 |
| Linzess | Linaclotide | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Cephalexin | Cephalexin | 15 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $851.58 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, Evoke, INSPIRE, JOBST SPORT, NURTEC ODT, Natroba, Ozempic, QULIPTA, Rybelsus, Senza, Spinosad, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error